Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced successful top-line results from its Phase 2 study of Zerenex™ (ferric citrate coordination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE